Alavi K, Schwartz MZ, Palazzo JP, Prasad R (2000) Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2
3 arGSTs catalyse the conversion of flavan-3,3,4-triol (4) into cyanidin (8)
It showed significant effectiveness in phase 3 trials (ATTAIN-1), reducing body weight by approximately 12.4% (about 27 pounds) at the highest dose (17.2 mg) over 72 weeks
Postmarketing Experience The following adverse reactions have been reported: Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine
Add in the fact that some people feel a little meh about food or water while on the meds, and youve got the perfect recipe for constipation
Both of these hormonal disruptions can partially counteract GLP-1 mediated appetite suppression